Compare VICR & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VICR | HALO |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.1B |
| IPO Year | 1995 | 2001 |
| Metric | VICR | HALO |
|---|---|---|
| Price | $334.08 | $67.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $217.50 | $78.64 |
| AVG Volume (30 Days) | 670.3K | ★ 1.5M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1764.29 | N/A |
| EPS | 0.44 | ★ 1.22 |
| Revenue | ★ $452,701,000.00 | $151,862,000.00 |
| Revenue This Year | $37.01 | $28.24 |
| Revenue Next Year | $39.47 | $12.56 |
| P/E Ratio | $737.76 | ★ $56.02 |
| Revenue Growth | ★ 26.08 | N/A |
| 52 Week Low | $41.76 | $51.06 |
| 52 Week High | $361.89 | $82.22 |
| Indicator | VICR | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 46.56 |
| Support Level | $140.71 | $66.31 |
| Resistance Level | $361.89 | $70.54 |
| Average True Range (ATR) | 23.22 | 2.34 |
| MACD | 0.58 | -0.28 |
| Stochastic Oscillator | 87.66 | 35.18 |
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others. The principal markets for the Company's power converters and systems are large original equipment manufacturers (OEMs), original design manufacturers (ODMs) and their contract manufacturers, and smaller, lower volume users, which are broadly distributed across several market areas.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.